Abstract
The development and proliferation of immune checkpoint inhibitors (CPI) as cancer therapies has represented a transformative shift for cancer treatment. The significant benefits accrued by patients receiving these drugs, however, often come at the cost of immune-related adverse events (irAE), which may occur in any organ system but are most commonly cutaneous (c-irAE). While the majority of these c-irAE can be successfully treated, they incur significant morbidity, and may cause the interruption or discontinuation of CPI treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
